NCT03835949: Study of TJ004309 in Combination With Atezolizumab (Tecentriq¬) in Patients With Advanced or Metastatic Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active or untreated brain or leptomeningeal metastases- see trial for details; Patients with prior T-cell therapy

Comments are closed.

Up ↑